Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTIS and RTC for Allogeneic Stem Cell Transplant in Inherited Hematologic Disorders
NCT05293509Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine, dexamethasone, cyclophosphamide, bortezomib, rituximab and 4 more in hereditary hematologic disorders, sponsored by University of Texas MD Anderson Cancer Center. Planned start Mar 2022; status: withdrawn.
02
Drugs
fludarabinedexamethasonecyclophosphamidebortezomibrituximab
03
Conditions
hereditary hematologic disorders
Beyond the preview
Go deeper on NCT05293509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293509.